The Science Behind Tirzepatide: A Dual Agonist Breakthrough in Medical Weight Loss
Tirzepatide targets two metabolic pathways at once — a dual GIP and GLP-1 receptor agonist clinically proven to reduce body weight by 20 to 22 percent, outperforming single agonist therapies.